New FDA approval for muscle-invasive bladder cancer

The U.S. Food and Drug Administration (FDA) has approved atezolizumab (Tecentriq) and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) for certain patients with muscle-invasive bladder cancer (MIBC) after bladder removal surgery (cystectomy). The FDA also approved Signatera CDx as the companion diagnostic test used to identify eligible patients.

This approval marks an important step toward more personalized cancer care by using circulating tumor DNA (ctDNA) testing to help identify which patients may benefit most from additional treatment.

What does this approval mean?

After surgery for MIBC, many patients face an uncertain “watch and wait” period. Even when scans show no visible cancer, microscopic cancer cells may still remain in the body and could lead to recurrence later.

This new approval introduces a more personalized approach using ctDNA testing, sometimes referred to as a “molecular residual disease” (MRD) test. ctDNA tests look for tiny fragments of tumor DNA circulating in the blood after surgery. A positive ctDNA test may indicate that cancer cells are still present, even before recurrence appears on imaging scans.

With this approval, patients whose ctDNA test becomes positive after cystectomy may now receive adjuvant immunotherapy with atezolizumab to help reduce the risk of the cancer returning.

According to Bladder Cancer Advocacy Network CEO Meri-Margaret Deoudes, this strategy may help doctors identify patients at higher risk of recurrence earlier, allowing them to begin treatment sooner while helping lower-risk patients avoid unnecessary side effects from additional therapy.

Why this is significant for patients

This approval is notable for several reasons:

1. It brings ctDNA testing further into routine cancer care

While ctDNA testing has been studied for several years, this is one of the first FDA approvals in bladder cancer that directly links a ctDNA result to a treatment decision. Instead of treating every patient the same after surgery, doctors can now use blood-based molecular testing to help guide next steps.

For patients, this may mean:

• More personalized treatment decisions
• Earlier identification of recurrence risk
• Potentially avoiding overtreatment if ctDNA remains negative
• Additional reassurance during surveillance after surgery

2. The treatment improved survival outcomes

The approval was based on results from the phase III IMvigor011 trial, which enrolled patients with MIBC who underwent cystectomy.

Patients underwent serial ctDNA testing for up to 12 months after surgery. Those who tested positive for MRD were randomly assigned to receive atezolizumab or placebo.

Researchers found that patients who received atezolizumab experienced:

• A median disease-free survival (DFS) of 9.9 months compared with 4.8 months for placebo
• A reduction in the risk of recurrence or death
• Improved overall survival, with median survival of 32.8 months compared with 21.1 months in the placebo group

These findings suggest that treating ctDNA-positive patients earlier may help delay recurrence and potentially extend survival.

What is atezolizumab?

Atezolizumab is an immunotherapy known as a PD-L1 inhibitor. It works by helping the immune system better recognize and attack cancer cells.

The drug has already been used in several cancer types, including bladder cancer, but this approval specifically applies to patients with:

• MIBC
• Prior cystectomy
• Positive ctDNA testing indicating measurable residual disease

The treatment may be given intravenously every two, three, or four weeks for up to one year. The newer formulation, atezolizumab and hyaluronidase-tqjs, is administered as a subcutaneous (under-the-skin) injection every three weeks.

What should patients know about ctDNA monitoring?

The FDA recommends ongoing serial ctDNA testing after surgery, even if the initial test is negative.

Patients who test negative with Signatera CDx should continue monitoring for up to 12 months or until a positive result is detected. This is important because ctDNA may become detectable later during surveillance.

For patients, this highlights how cancer monitoring is becoming more dynamic and individualized over time rather than relying solely on imaging scans or symptoms.

What are the possible side effects?

Like other immunotherapies, atezolizumab can cause immune-related side effects because it activates the immune system. Patients should discuss possible risks and benefits with their care team and report new symptoms promptly during treatment.

The bigger picture

This approval reflects a growing shift toward precision oncology, where treatment decisions are guided not only by the type of cancer, but also by molecular signals left behind after treatment.

For bladder cancer patients recovering from cystectomy, ctDNA-guided therapy may offer a more proactive way to identify recurrence risk earlier and intervene before cancer becomes clinically visible.

As ctDNA technology continues to evolve, experts hope this approach may eventually help personalize treatment decisions across many cancer types.

Outcomes4Me is here to help you better understand your diagnosis and treatment options. You deserve clear, trustworthy information at every step.